ArticleFrontiers in psychiatry2026
Social isolation, loneliness, disability progression, and mortality among older adults with cardiac disease: a longitudinal NHATS study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac disease is the leading cause of morbidity and mortality among older adults, yet the psychosocial pathways through which it accelerates functional decline remain poorly characterized. Social isolation and loneliness are plausible mediators, but their longitudinal roles in the cardiac disease-disability-mortality cascade have not been examined in an integrated framework. Methods: We analyzed 5,654 US Medicare beneficiaries aged ≥65 from the National Health and Aging Trends Study (NHATS) followed across Rounds 7-14 (2017-2024). Cardiac disease was ascertained at baseline via self-reported physician diagnosis. Social isolation was measured via a validated composite index; loneliness was assessed with a single-item measure. Disability outcomes included Nagi physical function, mobility limitation, activities of daily living (ADL) impairment, and instrumental activities of daily living (IADL) impairment. We estimated group differences using generalized estimating equations (GEE), mortality using Kaplan-Meier and Cox proportional-hazards models, and mediation using the counterfactual framework. Results: At baseline, 1,361 participants (24.1%) had cardiac disease. The CD group exhibited higher social isolation prevalence (19.2% vs 16.8%, p=0.048), lower Nagi scores (7.1 vs 8.5, p<0.001), and greater comorbidity burden (2.9 vs 2.1 conditions, p<0.001). Over follow-up, CD was associated with persistently worse physical function (Round 14 Nagi: 7.1 vs 8.1, p<0.001) and higher mobility limitation (25.2% vs 15.0%). Cumulative mortality reached 49.0% in the CD group vs 33.4% in the No CD group (log-rank χ²=121.97, p<0.001). Mediation analysis showed a negligible indirect effect through social isolation, corresponding to -1.4% of the CD→disability effect (path a: β=-0.0114, p=0.801; path b: β=-0.7002, p<0.001; NIE β=0.0080), indicating no meaningful mediation by baseline social isolation. Conclusions: Among older adults, cardiac disease was associated with disability progression and mortality, with little evidence that baseline social isolation explained the functional decline association. Although social isolation was more common among participants with cardiac disease, its contribution to functional decline was minimal, indicating that clinical and biological factors may play a larger role. Interventions targeting disability in cardiac disease should include biomedical and rehabilitative strategies while continuing to address social health as a parallel concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.